Now in press at CGH promising results PCB trial of curcumin-QingDai (CurQD) botanical combo. Shown to be a unique AhR agonist which was effective for active UC pts, half of whom IMM/biologics exprienced. my COI of note. American Gastroenterological Association (AGA) #nutrition cghjournal.org/article/S1542-…

And with these latest data I updated the timeline including guselkumab Feel free to use it at any time 😊

🎯 Extending the Half-Life of mAbs: Why It Matters in IBD In Crohn’s disease and ulcerative colitis, therapeutic monoclonal antibodies often require frequent dosing—which can burden patients and strain healthcare systems. 🧬 Enter Fc engineering: By tweaking the Fc region of

A bombshell metaanalysis just landed in CGH : Advanced therpies work better in colonic #Crohn vs. Ileal dis 😱 aTNFs/aIL23-aIL12/23 were all more effective in the colon, aIntegrin same efficacy in both(?), and JAKi were ONLY EFFECTIVE IN COLON.... cghjournal.org/article/S1542-…

This much-needed study 🧠📊 highlights how treatment efficacy in Crohn’s varies by disease location. Advanced therapies work much better in colonic CD vs. ileal — especially JAK inhibitors, which showed almost no benefit in ileal CD. #IBD cghjournal.org/article/S1542-…

The Helmsley Charitable Trust PIANO Global Consensus Statement will be in print in early August! Please join Millie Long and myself for a global webinar to review the recommendations. After the webinar, the slides will be released to the public. Link: ucsf.zoom.us/webinar/regist…

Efficacy and Safety of Vedolizumab & Tofacitinib (VETO) Combination Therapy in Refractory UC Unresponsive to Anti-TNF and Second-Line Advanced Therapy: A Prospective Cohort Nested Within a Randomised Trial by Dr. Rupa Banerjee Pardhu Bharath Dr Rajendra Patel roypounder.apt onlinelibrary.wiley.com/doi/10.1111/ap…

Currently listening to Dr. Uma Mahadevan and Dr. Millie Long on managing #IBD in pregnancy — excellent discussion on preconception planning, medication safety, and the latest insights from the PIANO study. 📊👩‍⚕️ #Gastroenterology #PIANOstudy

If you missed the PIANO Global Consensus Webinar today with me & Millie Long, please go to pianostudy.org to... ☑️Watch the webinar ☑️ Download the slides (English/Spanish) ☑️ Watch the patient video (7 languages) ☑️ Enroll in the PIANO study Embargo date epub: 8/22/25

Latest edition of Permanente Excellence is out! Thank you TPMG Physician Careers and Smita Rouillard, MD for featuring and supporting our unique, collaborative, and regional team-based approach to IBD care across Northern California. It takes a village. I am grateful to our TPMG physicians,

Distinguishing iron deficiency anaemia (IDA) from anaemia of chronic disease (ACD) 💡 📸: fg.bmj.com/content/early/…

#MondayNightIBD 🎥 series starts now🚦How to incorporate #IBD trials in your practice w/ Jana G Hashash, MD, MSc & Aline Charabaty, MD, FACG, AGAF x.com/i/broadcasts/1…

How long treatments take to work in IBD ⏱️💊 📸: gut.bmj.com/content/74/Sup…

GLOBAL CONSENSUS: MANAGEMENT OF PREGNANCY AND IBD NOW ONLINE! Free link: doi.org/10.1016/j.cgh.… Jointly published: CGH AJG - The American Journal of Gastroenterology Gut Journal IBDJournal & CC360 Journal of Crohn's and Colitis roypounder.apt 🙏Helmsley Charitable Trust for the support & all the scientists & patients who participated! PIANO Millie Long

Such a privilege to work with Dr. Velayos Fernando Velayos MD MPH & the IBD team 🙏 Always learning, always inspired—honored to support our patients together 💙

Positioning thiopurines in IBD in 2025 Nice talk for a difficult topic by Sophie Restellini at Swiss IBDnet

#MondayNightIBD 🎥series cont...w/ Bruce E. Sands on #IBD trials ~ 🎯Anti-IL23, what’s next for this MOA? 🎯Dual target therapy RCT to watch for 🔮 x.com/i/broadcasts/1…

JAKi review of their use and position in IBD therapy #UEGweek my_UEG by Sebastian Zessig

Big news! Something that clinically makes sense from U.S. FDA RINVOQ: (NEW ADDITION) If TNF blockers are clinically inadvisable, patients should have received at least one approved systemic therapy prior to use of RINVOQ.

Ustekinumab > vedolizumab for chronic pouchitis onlinelibrary.wiley.com/doi/10.1111/ap…